Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Core Insights - Adverum Biotechnologies has appointed Jason L. Mitchell as chief commercial officer, who has over 20 years of experience in the commercial sector, particularly in retinal diseases [1][2] - The company is advancing its gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), which is currently in Phase 2 clinical trials and aims to establish a new standard of care for wet age-related macular degeneration (wet AMD) [1][5] - Adverum plans to announce 52-week data from the LUNA trial and pivotal program details in Q4 2024, with the initiation of the pivotal program expected in the first half of 2025 [1][2] Company Overview - Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies for prevalent ocular diseases, aiming to restore vision and prevent blindness [4][5] - The company utilizes a proprietary intravitreal (IVT) platform to create durable, single-administration therapies that reduce the need for frequent ocular injections [5] Leadership Background - Jason L. Mitchell previously led the successful launch of SYFOVRE® for geographic atrophy and has held significant roles in sales, marketing, and operations at various pharmaceutical companies [2][3] - His expertise is expected to enhance Adverum's strategy for introducing Ixo-vec as a leading gene therapy for wet AMD [2]